Recombinant Anti-beta Catenin antibody [BLR086G] (ab265591)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [BLR086G] to beta Catenin
- Suitable for: WB, IP, ICC, IHC-P
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-beta Catenin antibody [BLR086G]
See all beta Catenin primary antibodies -
Description
Rabbit monoclonal [BLR086G] to beta Catenin -
Host species
Rabbit -
Tested applications
Suitable for: WB, IP, ICC, IHC-Pmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide within Human beta Catenin aa 725-775. The exact sequence is proprietary. NP_001895.1
Database link: P35222 -
Positive control
- IHC-P: Human colon carcinoma tissue, human plasmacytoma, human prostate carcinoma. ICC: OVCAR-3 cells. WB: HepG2, LNCaP, GaMG, A549, MCF7, HeLa, TCMK and NIH/3T3 whole cell lysate. IP: HeLa and HepG2 whole cell lysate.
-
General notes
This product is sold under License from Bethyl Laboratories, Inc.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.8
Preservative: 0.09% Sodium azide
Constituents: 98% Borate buffered saline, 0.1% BSA -
Concentration information loading... -
Purity
Affinity purified -
Purification notes
Purified from TCS. -
Clonality
Monoclonal -
Clone number
BLR086G -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Positive Controls
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab265591 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB |
1/1000. Predicted molecular weight: 85 kDa.
|
|
| IP |
Use at an assay dependent concentration.
20 µl/mg lysate. |
|
| ICC |
1/100 - 1/500.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with ICC staining protocol. |
|
| IHC-P |
1/100 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
| Notes |
|---|
|
WB
1/1000. Predicted molecular weight: 85 kDa. |
|
IP
Use at an assay dependent concentration. 20 µl/mg lysate. |
|
ICC
1/100 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with ICC staining protocol. |
|
IHC-P
1/100 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
Function
Key dowstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes.
Involved in the regulation of cell adhesion. The majority of beta-catenin is localized to the cell membrane and is part of E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton. -
Tissue specificity
Expressed in several hair follicle cell types: basal and peripheral matrix cells, and cells of the outer and inner root sheaths. Expressed in colon. -
Involvement in disease
Defects in CTNNB1 are associated with colorectal cancer (CRC) [MIM:114500].
Note=Activating mutations in CTNNB1 have oncogenic activity resulting in tumor development. Somatic mutations are found in various tumor types, including colon cancers, ovarian and prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant embryonal tumors mainly affecting young children in the first three years of life.
Defects in CTNNB1 are a cause of pilomatrixoma (PTR) [MIM:132600]; a common benign skin tumor.
Defects in CTNNB1 are a cause of medulloblastoma (MDB) [MIM:155255]. MDB is a malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.
Defects in CTNNB1 are a cause of susceptibility to ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.
Note=A chromosomal aberration involving CTNNB1 is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1. -
Sequence similarities
Belongs to the beta-catenin family.
Contains 12 ARM repeats. -
Post-translational
modificationsPhosphorylation by GSK3B requires prior phosphorylation of Ser-45 by another kinase. Phosphorylation proceeds then from Thr-41 to Ser-37 and Ser-33.
EGF stimulates tyrosine phosphorylation. Phosphorylation on Tyr-654 decreases CDH1 binding and enhances TBP binding.
Ubiquitinated by the SCF(BTRC) E3 ligase complex when phosphorylated by GSK3B, leading to its degradation. Ubiquitinated by a E3 ubiquitin ligase complex containing UBE2D1, SIAH1, CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent proteasomal degradation. -
Cellular localization
Cytoplasm. Nucleus. Cytoplasm > cytoskeleton. Cell junction > adherens junction. Cell junction. Cell membrane. Cytoplasmic when it is unstabilized (high level of phosphorylation) or bound to CDH1. Translocates to the nucleus when it is stabilized (low level of phosphorylation). Interaction with GLIS2 and MUC1 promotes nuclear translocation. Interaction with EMD inhibits nuclear localization. - Information by UniProt
-
Database links
- Entrez Gene: 1499 Human
- Entrez Gene: 12387 Mouse
- Omim: 116806 Human
- SwissProt: P35222 Human
- SwissProt: Q02248 Mouse
- Unigene: 476018 Human
- Unigene: 291928 Mouse
-
Alternative names
- b-catenin antibody
- Beta catenin antibody
- Beta-catenin antibody
see all
Images
-
Western blot - Anti-beta Catenin antibody (ab265591)All lanes : Anti-beta Catenin antibody [BLR086G] (ab265591) at 1/1000 dilution
Lane 1 : HepG2 whole cell lysate
Lane 2 : LNCaP whole cell lysate
Lane 3 : K562 whole cell lysate
Lane 4 : GaMG whole cell lysate
Lane 5 : Jurkat whole cell lysate
Lane 6 : A549 whole cell lysate
Lane 7 : MCF7 whole cell lysate
Lane 8 : HeLa whole cell lysate
Lane 9 : TCMK whole cell lysate
Lane 10 : NIH/3T3 whole cell lysate
Lysates/proteins at 50 µg per lane.
Secondary
All lanes : HRP-conjugated goat anti-rabbit IgG
Predicted band size: 85 kDa
Exposure time: 10 secondsCells prepared using NETN lysis buffer.
-
Immunocytochemistry - Anti-beta Catenin antibody (ab265591)Immunocytochemical analysis of formalin-fixed, paraffin-embedded OVCAR-3 (Human ovarian carcinoma cell line) cells labeling beta Catenin with ab265591 at 1/100 dilution. Detection: DAB.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Catenin antibody (ab265591)Immunohistochemical analysis of formalin-fixed, paraffin-embedded human colon carcinoma tissue labeling beta Catenin with ab265591 at 1/100 dilution. Detection: DAB.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Catenin antibody (ab265591)Immunohistochemical analysis of formalin-fixed, paraffin-embedded human plasmacytoma tissue labeling beta Catenin with ab265591 at 1/100 dilution. Detection: DAB.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Catenin antibody [BLR086G] (ab265591)](https://www.abcam.com/ps/products/265/ab265591/Images/ab265591-466806-ab265591-anti-beta-catenin-recombinant-monoclonal-antibody-human-prostate-carcinoma-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Catenin antibody [BLR086G] (ab265591)Immunohistochemical analysis of formalin-fixed, paraffin-embedded human prostate carcinoma, labeling beta Catenin with ab265591. HRP-conjugated goat anti-rabbit IgG used as the secondary antibody. DAPI counterstain.
-
Immunoprecipitation - Anti-beta Catenin antibody (ab265591)beta Catenin was immunoprecipitated from 1mg of HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate with ab265591 at 20 µl per reaction. Western blot was performed from the immunoprecipitate using ab265591 at 1/1000 dilution.
Lane 1: ab265591 IP in HeLa whole cell lysate.
Lane 2: Control IgG.Exposure time: 3 secs.
Cells prepared using NETN lysis buffer.
-
Immunoprecipitation - Anti-beta Catenin antibody (ab265591)beta Catenin was immunoprecipitated from 1mg of HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate with ab265591 at 20 µl per reaction. Western blot was performed from the immunoprecipitate using ab265591 at 1/1000 dilution.
Lane 1: ab265591 IP in HeLa whole cell lysate.
Lane 2: Control IgG.Exposure time: 3 secs.
Cells prepared using NETN lysis buffer.
-
![Anti-beta Catenin antibody [BLR086G] (ab265591)](https://www.abcam.com/ps/products/265/ab265591/Images/ab265591-7-benefits-of-recombinant-antibodies.png)
Anti-beta Catenin antibody [BLR086G] (ab265591)
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab265591 has not yet been referenced specifically in any publications.